EG201

EG201 is a preclinical-stage gene therapy candidate being developed by Elisigen for the treatment of chronic neuropathic pain. The therapy utilizes an adeno-associated virus (AAV) vector to deliver a therapeutic genetic payload designed to modulate pain signaling pathways in the peripheral nervous system. By targeting the underlying molecular mechanisms of neuropathic pain, EG201 aims to provide long-lasting analgesia through a single administration, potentially offering a safer and more effective alternative to traditional systemic pharmacological treatments such as opioids or anticonvulsants. The program is part of Elisigen's broader pipeline of AAV-based gene silencing therapies for neurological and pain disorders.